A German multicenter, randomized, controlled, open-label study of the Cypher sirolimus-eluting stent in the treatment of diabetic patients with de novo native coronary artery lesions.

Trial Profile

A German multicenter, randomized, controlled, open-label study of the Cypher sirolimus-eluting stent in the treatment of diabetic patients with de novo native coronary artery lesions.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Mar 2012

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms SCORPIUS
  • Sponsors Cordis Corporation
  • Most Recent Events

    • 02 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top